Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/11/2010Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2010 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2011 Guidance
CINCINNATI, Nov 11, 2010 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS reported fourth quarter and full-year fiscal 2010 net sales of $35.5 million and $143.0 million, respectively, decreases of 16% and 4%, respectively, from the same periods of the prior fiscal year; reported fourth quarter and full-year fiscal 2010 operating income of $8.5 million and $41.1 million, respectively, dec... 
 Printer Friendly Version
9/30/2010Meridian Bioscience Receives Canadian License for illumigene(TM) C. difficile
CINCINNATI, Sep 30, 2010 (BUSINESS WIRE) --Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular amplification assay detects the presence of the toxin p... 
 Printer Friendly Version
9/13/2010Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2011 and Updates Fiscal 2010 Guidance
CINCINNATI, Sep 13, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2011 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2011, management expects net sales to be in the range of $165 to $170 million and per share diluted earnings to be between $0.77 and $0.82. The per share estimates assume ... 
Download PDFPrinter Friendly Version
7/20/2010Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2010 Guidance
CINCINNATI, Jul 20, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported third quarter net sales of $33.9 million, a decrease of 11% compared to the same period of the prior fiscal year; reported record nine months net sales of $107.5 million, an increase of 2%, compared to the same period of the prior fiscal year; reported third quarter and nine months operating income of $9.8... 
Download PDFPrinter Friendly Version
7/20/2010Meridian Bioscience Acquires Leading Manufacturer and Distributor of Molecular Reagents
CINCINNATI, Jul 20, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand. Bioline, headquartered in London, is a leading manufacturer and distributor of molecula... 
Download PDFPrinter Friendly Version
7/13/2010Meridian Bioscience Receives FDA Clearance for New illumigene(TM) Molecular Platform
CINCINNATI, Jul 13, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its new molecular amplification assay, illumigene(TM) C.difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular amplification assay detects the presence of the toxin producing region from... 
Download PDFPrinter Friendly Version
7/7/2010Meridian Bioscience, Inc. Enters into Product Development and Distribution Agreement with DiaSorin S.p.A.
CINCINNATI, Jul 07, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has entered into an exclusive, world-wide product development and distribution agreement with DiaSorin S.p.A. Under terms of the agreement, DiaSorin will utilize key Meridian technology to develop several infectious disease products for use on their LIAISON(R) systems. LIAISON is a fully automated, random access system based on chemiluminescense detection. There are ov... 
Download PDFPrinter Friendly Version
4/20/2010Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2010 Guidance
CINCINNATI, Apr 20, 2010 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported second quarter net sales of $31.1 million, a decrease of 6% compared to the same period of the prior fiscal year; reported record six months net sales of $73.6 million, an increase of 9%, compared to the same period of the prior fiscal year; reported second quarter and six months operating income of $9.1 mi... 
Download PDFPrinter Friendly Version
3/22/2010Meridian Bioscience Submits New illumigene(TM) Molecular C. difficile Test to U.S. FDA for Marketing Clearance
CINCINNATI, Mar 22, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc. announced today that it has submitted a 510(k) application to the United States Food and Drug Administration for marketing clearance of its new, simple molecular diagnostic test, illumigene(TM) C. difficile. illumigene is a simplified new technology platform, based upon loop amplification (LAMP) that makes molecular diagnostic testing possible for any size laboratory. The technology is isothermal and therefore requires no cost... 
Download PDFPrinter Friendly Version
3/17/2010Meridian Bioscience Revises Guidance for Fiscal 2010 and Comments on Preliminary Second Quarter Operating Results and Business Outlook Including illumigene(TM) Update
CINCINNATI, Mar 17, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in ... 
Download PDFPrinter Friendly Version
1/21/2010Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2010 Guidance
CINCINNATI, Jan 21, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record first quarter net sales of $42.5 million, an increase of 24%, over the same period of the prior fiscal year; reported record first quarter operating income of $13.8 million, an increase of 13%, over the same period of the prior fiscal year; reported record first quarter earnings and diluted earnings... 
Download PDFPrinter Friendly Version